Evidence map›Paper›PMID 27226230›Full record

ArticleProteomics2016

MALDI-MSI for the analysis of a 3D tissue-engineered psoriatic skin model.

Amanda Harvey, Laura M Cole, Rebecca Day, Maggie Bartlett, John Warwick, Richard Bojar, David Smith, Neil Cross, Malcolm R Clench

Open access · hybridAbstract read
In one paragraph

Article in Proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. -Omics potential of in vitro skin models for radiation exposure.Cellular and molecular life sciences : CMLS · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Proteomics in Psoriasis.International journal of molecular sciences · 2019
    Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Amanda HarveyCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Laura M ColeCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Rebecca DayCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Maggie BartlettInnovenn, Sand Hutton Innovation Campus, York, UK.
John WarwickInnovenn, Sand Hutton Innovation Campus, York, UK.
Richard BojarInnovenn, Sand Hutton Innovation Campus, York, UK.
David SmithCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Neil CrossCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Malcolm R ClenchCentre for Mass Spectrometry Imaging, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
Sheffield Hallam University · GBInnovate UK · GB

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L001896/1
6 · The paper itself

Abstract

MALDI-MS Imaging is a novel label-free technique that can be used to visualize the changes in multiple mass responses following treatment. Following treatment with proinflammatory cytokine interleukin-22 (IL-22), the epidermal differentiation of Labskin, a living skin equivalent (LSE), successfully modeled psoriasis in vitro. Masson's trichrome staining enabled visualization and quantification of epidermal differentiation between the untreated and IL-22 treated psoriatic LSEs. Matrix-assisted laser desorption ionization mass spectrometry imaging was used to observe the spatial location of the psoriatic therapy drug acetretin following 48 h treatments within both psoriatic and normal LSEs. After 24 h, the drug was primarily located in the epidermal regions of both the psoriatic and nonpsoriatic LSE models whereas after 48 h it was detectible in the dermis.

Indexed as

AnimalsCell DifferentiationDisease Models, AnimalEpidermisHumansImaging, Three-DimensionalInterleukin-22InterleukinsMicePsoriasisSkinSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTissue EngineeringInterleukin-22InterleukinsAcetretinInterleukin-22Living skin equivalentMALDI-MSIPsoriasisSkinTechnologyTissue engineering

Identifiers

PMID27226230
PMCPMC5094548
OpenAlexW2404396276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.